ClinicalTrials.gg
CompletedNCT03122899SALLYUpdated Jun 5, 2025

Study of Bone Growth in the Sacroiliac Joint After Minimally Invasive Surgery With Titanium Implants

An interventional study of SIJ fusion with iFuse-3D in Sacroiliac Dysfunction, sponsored by SI-BONE, Inc.. Completed at 11 sites in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by SI-BONE, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Study summary

SALLY studies sacroiliac joint fusion with the iFuse-3D implant.

Read the detailed description

Participants will all get sacroiliac joint fusion on this study using the iFuse-3D titanium implant, manufactured by SI-BONE, Inc. Participants will be followed for clinical outcomes at pre-planned time points on the trial. Participants will be randomized to CT scan at 6 months or 12 months, and all will also get a CT scan at 5 years, the final visit for the study.

02

Conditions studied

  • Sacroiliac Dysfunction

Keywords

  • SI-BONE
  • sacroiliac joint
  • degenerative sacroiliitis
  • sacroiliac joint disruption
  • iFuse
03

In context

Lead sponsor

SI-BONE, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient age 21-70 at time of screening.
  2. Patient has suspected SI joint pain for greater than or equal to 6 months inadequately responsive to conservative care.
  3. Diagnosis of sacroiliac joint dysfunction on one or two sides to be treated on study that is a direct result of sacroiliac joint disruption and/or degenerative sacroiliitis and is based on ALL of the following:

    1. Patient has pain at or close to the posterior superior iliac spine (PSIS) with possible radiation into buttocks, posterior thigh or groin and can point with a single finger to the location of pain (Fortin Finger Test) (on any targeted side), and
    2. Patient has positive findings on at least 3 physical examination maneuvers that stress the target SI joint(s) and
    3. Patient has block on any study targeted side with improvement in SI joint pain numeric rating scale (NRS) at 30 or 60 minutes of at least 50% after injection of local anesthetic into any affected SI joint with an immediate pre-block NRS of at least 5.
  4. Baseline Oswestry Disability Index (ODI) score of at least 30%.
  5. Baseline (average over the last week) SI joint pain score of at least 50 on 0-100 mm visual analog scale on any side to be treated under the study.
  6. Patient has signed study-specific form.
  7. Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements.
  8. Patient's insurance coverage for SI joint treatment has been considered and plan is to submit all study-related healthcare to insurance (or it is the patient's responsibility) (any required preauthorization should be completed prior to randomization on study).
  9. Investigator believes patient is appropriate candidate for surgery using iFuse-3D Implant.

Exclusion criteria

Exclusion Criteria:

  1. Patient has bilateral SI joint symptoms with VAS pain scores ³50 on both sides and patient refuses to undergo bilateral treatment according to the study protocol.
  2. Patient is currently pregnant, actively trying to become pregnant or is planning to become pregnant in the next year.
  3. Severe back or hip pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, lumbar vertebral body fracture, piriformis syndrome, femoral acetabular impingement, labral tear or hip osteoarthritis. Patients with low back pain VAS ratings more than 50 should be carefully considered; they should not participate if the investigator believes these non-SIJ conditions would impair improvement from SIJ treatment.
  4. SI joint dysfunction due to an alternative explanation such as:

    1. Inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondyloarthropathy)
    2. Tumor
    3. Infection
    4. Acute or unstable fracture.
  5. History of recent (\<1 year) major non-pregnancy-related trauma to pelvis.
  6. Surgeon believes patient body habitus prevents surgery.
  7. Previously diagnosed osteoporosis (defined as prior T-score \<-2.5 or history of osteoporotic fracture) or prior/current use of drug therapy for osteoporosis.
  8. Prior fracture of any bone related to cancer/tumor (i.e., pathologic fracture).
  9. Prior diagnosis of tumor in sacrum or ilium.
  10. Unstable fracture of sacrum and or ilium involving the targeted SIJ.
  11. Osteomalacia or other metabolic bone disease.
  12. Diagnosed or suspected chronic rheumatologic condition (e.g., rheumatoid arthritis, lupus).
  13. Any known condition or anatomical deformity or variation that makes treatment with the iFuse-3D Implant infeasible.
  14. Any known health condition that could prevent long-term follow-up required in this study.
  15. Known allergy to titanium or titanium alloys.
  16. Use of medications known to have detrimental effects on bone quality and soft-tissue healing.
  17. Current local or systemic infection that raises the risk of surgery.
  18. Patient currently receiving or seeking short- or long-term worker's compensation related to the SI joint or low back pain, currently receiving disability remuneration related to SI joint or low back pain, and/or currently involved in injury litigation related to the SI joint or low back pain.
  19. Patient is a prisoner or a ward of the state.
  20. Patient has known or suspected active drug or alcohol abuse.
  21. Patient is unwilling to sign the study-associated opioid contract.
  22. Diagnosed uncontrolled psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation.
  23. Patient is participating in an study or has been involved in an investigational study within 3 months prior to evaluation for participation.
  24. Patient has known or suspected fibromyalgia.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Other
    SIJ fusion with iFuse 3D with 6 mo CT

    These subjects will get pelvic CT at 6 months post-operatively.

    Device: SIJ fusion with iFuse-3D

  • Other
    SIJ fusion with iFuse 3D with 12 mo CT

    These subjects will get pelvic CT at 12 months post-operatively.

    Device: SIJ fusion with iFuse-3D

Interventions

  • DeviceSIJ fusion with iFuse-3D

    Minimally invasive SIJ fusion with iFuse-3D titanium implant (usually 3 implants per SIJ).

06

What researchers measure

Primary outcomes

  1. Primary Radiographic Outcome: Bone adherence

    Percent surface area of the sacral end of the implants to which bone is adherent.

    Time frame: Comparing 6 and 12 month CTs to historical data from other studies.

  2. Primary Clinical Outcome: Disability due to low back pain

    Improvement in Oswestry Disability Index

    Time frame: Comparing baseline to 6 months.

Secondary outcomes

  1. Bridging Bone

    Proportion of treated SIJs with bridging bone.

    Time frame: 6 months, 12 months, and 5 years

  2. Clinically Significant Radiolucency

    Proportion of treated SIJs with evidence of clinically significant radiolucency.

    Time frame: 6 months, 12 months, and 5 years

  3. Adverse Bone Reactions

    Proportion of treated SIJs with adverse bone reactions at or near the SIJ.

    Time frame: 6 months, 12 months, and 5 years

  4. Positive Bone Remodeling

    Proportion of treated SIJs with positive bone remodeling response.

    Time frame: 6 months, 12 months, and 5 years

  5. SIJ Pain

    Improvement from baseline in SIJ pain as measured by Visual Analog Scale

    Time frame: Baseline, 3 mo, 6 mo, 12 mo, 24 mo, 60 months.

  6. Disability

    Improvement from baseline in disability as measured by Oswestry Disability Index.

    Time frame: Baseline, 3 mo, 6 mo, 12 mo, 24 mo, 60 months.

  7. QOL

    Improvement from baseline in QOL as measured by EQ-5D

    Time frame: Baseline, 3 mo, 6 mo, 12 mo, 24 mo, 60 months.

  8. Physical Function

    Improvement from baseline in physical function as measured by active straight leg raise, 5 times sit to stand, transitional timed up and go.

    Time frame: Baseline, 3 mo, 6 mo, 12 mo, 24 mo, 60 months.

  9. Opioid Use

    Decrease from baseline in opioid use

    Time frame: Baseline, 3 mo, 6 mo, 12 mo, 24 mo, 60 months.

  10. Serious Adverse Event Rate

    Rate of serious adverse events related to the procedure or device.

    Time frame: 3 mo, 6 mo, 12 mo, 24 mo, 60 months.

07

Study locations

11 sites
  • Memorial Orthopaedic Surgical Group
    Long Beach, California 90806, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Clin Tech Center for Spine Health
    Johnstown, Colorado 80534, United States
  • The B.A.C.K. Center
    Melbourne, Florida 32901, United States
  • Orthopedic Center of Southern Illinois
    Mount Vernon, Illinois 62864, United States
  • Bluegrass Orthopaedics
    Lexington, Kentucky 40509, United States
  • LSU Health Sciences Center, Department of Neurosurgery
    New Orleans, Louisiana 70112, United States
  • Columbia Orthopaedic Group
    Columbia, Missouri 65201, United States
  • South Oregon Orthopedics
    Medford, Oregon 97504, United States
  • Overlake Hospital Medical Center
    Bellevue, Washington 98004, United States
  • Aurora Research Institute
    Green Bay, Wisconsin 54311, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Jun 2024, 80 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2017
First posted
Apr 21, 2017
StartActual
Oct 3, 2017
Primary completionActual
Jun 19, 2024
CompletionActual
Jun 19, 2024
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03122899
Lead sponsor
SI-BONE, Inc.
Responsible party
Sponsor
First posted
Apr 21, 2017
Start date
Oct 3, 2017
Primary completion
Jun 19, 2024
Completion
Jun 19, 2024
Last update
Jun 5, 2025

Study contacts

Daniel J Cher, MD
study director · SI-BONE, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion